Cite
HARVARD Citation
Hamid, O. et al. (2014). A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma. Cancer. 120 (13), pp. 2016-2024. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Hamid, O. et al. (2014). A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma. Cancer. 120 (13), pp. 2016-2024. [Online].